Results 161 to 170 of about 34,512 (245)

Mutant IDH1 Is an Effective Immunotherapeutic Target for Glioma [PDF]

, 2014

openalex   +1 more source

Utility of IDH1/2 mutations as biomarkers for detection of measurable residual disease in acute myeloid leukemia. [PDF]

Blood Adv
Boertjes EL, Vonk CM, Kavelaars FG, Engvall M, Nordin S, Beugelink L, Rijken M, Konijnenburg JML, Versluis J, Löwenberg B, Valk PJM.   +10 more
europepmc   +1 more source

IDH1 mutation is associated with seizures and protoplasmic subtype in patients with low‐grade gliomas [PDF]

, 2014
Simon V. Liubinas, Giovanna M. D’Abaco, Bradford A. Moffat, Michael Gonzales, Frank Feleppa, Cameron J. Nowell, Alexandra Gorelik, Katharine J. Drummond, Terence J. O’Brien, Andrew H. Kaye, Andrew Morokoff   +10 more
openalex   +1 more source

Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab

, 2012
Shasha Lv, Erik Teugels, Jan Sadones, Sylvia De Brakeleer, Johnny Duerinck, Stephanie Du Four, Alex Michotte, Jacques De Grève, Bart Neyns   +8 more
openalex   +2 more sources

Isocitrate Dehydrogenase 1 (IDH1) Mutation in Breast Adenocarcinoma Is Associated With Elevated Levels of Serum and Urine 2-Hydroxyglutarate [PDF]

, 2014
Amir T. Fathi, Hossein Sadrzadeh, Amy Comander, Michaela J. Higgins, Aditya Bardia, Ashley Perry, Meghan Burke, Regina Silver, Christina R. Matulis, Kimberly Straley, Katharine Yen, Sam Agresta, Hyeryun Kim, David P. Schenkein, Darrell R. Borger   +14 more
openalex   +1 more source

Role of Multiparametric Ultrasound in Predicting the IDH Mutation in Gliomas: Insights from Intraoperative B-Mode, SWE, and SMI Modalities. [PDF]

J Clin Med
Cai S, Xing H, Wang Y, Wang Y, Ma W, Jiang Y, Li J, Wang H.   +7 more
europepmc   +1 more source

The NADP+-dependent IDH1 mutation and its relevance for glioblastoma patient survival [PDF]

, 2014
Cornelis J.F. Van Noorden
openalex   +1 more source

Joint prediction of glioma molecular marker status based on GDI-PMNet. [PDF]

J Transl Med
Zhu H, Liang F, Zhao T, Cao Y, Chen Y, Yan H, Xiao X.   +6 more
europepmc   +1 more source

Integrated genomic characterization of IDH1-mutant glioma malignant progression [PDF]

, 2015
Hanwen Bai, Akdes Serin Harmancı, E. Zeynep Erson‐Omay, Jie Li, Süleyman Coşkun, Matthias Simon, Boris Krischek, Koray Özduman, Sacit Bulent Omay, Eric A. Sorensen, Şevin Turcan, Mehmet Bakırcığlu, Geneive Carrión-Grant, Phillip B. Murray, Victoria Clark, A. Gulhan Ercan‐Sencicek, James Knight, Leman Sencar, Selin Altınok, Leon D. Kaulen, Burcu Gülez, Marco Timmer, Johannes Schramm, Ketu Mishra-Gorur, Octavian Henegariu, Jennifer Moliterno, Angeliki Louvi, Timothy A. Chan, Stacey Tannheimer, M. Necmettin Pamir, Alexander O. Vortmeyer, Kaya Bilgüvar, Katsuhito Yasuno, Murat Günel   +33 more
openalex   +1 more source

Proteomic Analysis Uncovers Enhanced Inflammatory Phenotype and Distinct Metabolic Changes in IDH1 Mutant Glioma Cells. [PDF]

Int J Mol Sci
Ravn Berg S, Brambilla A, Hagen L, Sharma A, Vågbø CB, Liabakk NB, Kissova M, Arano Barenys M, Bjørås M, Torp SH, Slupphaug G.   +10 more
europepmc   +1 more source